Rice Hall James & Associates LLC Has $1.76 Million Stake in Omnicell, Inc. $OMCL

Rice Hall James & Associates LLC raised its stake in Omnicell, Inc. (NASDAQ:OMCL) by 47.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 57,936 shares of the company’s stock after acquiring an additional 18,706 shares during the period. Rice Hall James & Associates LLC’s holdings in Omnicell were worth $1,764,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Inspire Investing LLC boosted its stake in shares of Omnicell by 13.5% in the 3rd quarter. Inspire Investing LLC now owns 15,011 shares of the company’s stock valued at $457,000 after purchasing an additional 1,787 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in Omnicell by 784.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock valued at $36,000 after purchasing an additional 1,036 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Omnicell by 1,316.2% in the third quarter. Assenagon Asset Management S.A. now owns 140,675 shares of the company’s stock valued at $4,284,000 after buying an additional 130,742 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in Omnicell by 1.2% in the second quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock valued at $1,013,000 after buying an additional 424 shares in the last quarter. Finally, Liontrust Investment Partners LLP grew its stake in Omnicell by 81.2% during the second quarter. Liontrust Investment Partners LLP now owns 318,284 shares of the company’s stock worth $9,358,000 after buying an additional 142,629 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently issued reports on OMCL shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of Omnicell in a research note on Wednesday, October 8th. Benchmark raised their price target on Omnicell from $45.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Finally, Zacks Research lowered Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 9th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $43.00.

Omnicell Stock Performance

OMCL stock opened at $46.40 on Friday. The company has a 50 day moving average price of $37.87 and a 200 day moving average price of $33.01. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $47.69. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.44 and a quick ratio of 1.21. The stock has a market capitalization of $2.08 billion, a PE ratio of 107.91, a price-to-earnings-growth ratio of 5.08 and a beta of 0.83.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.